We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

43 hedge funds and large institutions have $2.79M invested in Galectin Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

274% more call options, than puts

Call options by funds: $86K | Put options by funds: $23K

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

9.7% more ownership

Funds ownership: 0% → 9.7% (+9.7%)

7% less funds holding

Funds holding: 46 → 43 (-3)

19% less capital invested

Capital invested by funds: $3.43M → $2.79M (-$639K)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
7
Closed
8
Calls
$86K
Puts
$23K
Net Calls
+$63K
Net Calls Change
+$85K

Top Buyers

Rank Fund Capital Flow
1
DADC
D.A. Davidson & Co
Montana
+$108K
2
BCA
Benchmark Capital Advisors
New York
+$71.1K
3
ARTA
A.R.T. Advisors
New York
+$28.2K
4
LWAC
Laurel Wealth Advisors (California)
California
+$8.89K
5
BFA
BlackRock Fund Advisors
California
+$2.09K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$158K
2
SM
Sabby Management
Florida
-$78.2K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$55.7K
4
AG
Advisor Group
Arizona
-$37.6K
5
Wolverine Trading
Wolverine Trading
Illinois
-$35K
Name Holding Trade Value Shares
Change 		Change in
Stake
LWAC
26
Laurel Wealth Advisors (California)
California
$9K +$8.89K +10,000 New
Morgan Stanley
27
Morgan Stanley
New York
$7K -$140 -158 -2%
IA
28
IFP Advisors
Florida
$6K -$889 -1,000 -14%
WAM
29
Wolverine Asset Management
Illinois
$6K – – –
BIM
30
BlackRock Investment Management
Delaware
$5K – – –
Wells Fargo
31
Wells Fargo
California
$4K – – –
IWM
32
IHT Wealth Management
Illinois
$2K +$1.78K +2,000 New
First Manhattan
33
First Manhattan
New York
$1K – – –
NFG
34
Next Financial Group
Texas
$1K – – –
PRS
35
Pinkerton Retirement Specialists
Idaho
$1K – – –
UBS Group
36
UBS Group
Switzerland
$1K +$747 +841 New
Jacobs Levy Equity Management
37
Jacobs Levy Equity Management
New Jersey
– -$158K -139,714 Closed
SM
38
Sabby Management
Florida
– -$78.2K -87,999 Closed
Wolverine Trading
39
Wolverine Trading
Illinois
– -$35K -29,056 Closed
Citadel Advisors
40
Citadel Advisors
Florida
– -$22.9K -25,771 Closed
TSS
41
Two Sigma Securities
New York
– -$17K -15,429 Closed
AIM
42
Acrospire Investment Management
Illinois
– -$6K -5,500 Closed
MFS
43
MSI Financial Services
Massachusetts
– -$5K -4,194 Closed
LTFS
44
Ladenburg Thalmann Financial Services
Florida
– -$1K -708 Closed
RFM
45
Royal Fund Management
Florida
– +$6 +7 New
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
– +$148 +167 New
Creative Planning
47
Creative Planning
Kansas
– +$300 +338 +225%
1
2

GALT Hedge Fund Activity: Q4 2016 in Review

43 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2016, worth a combined $2.79M — down 19% from $3.43M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GALT and 6 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 9 added.

The largest buyer was D.A. Davidson & Co, adding an estimated $108K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $158K sold.

  • 43 institutional investors held Galectin Therapeutics (GALT) as of Q4 2016, down from 46 in Q3 2016.
  • Funds reported $2.79M of Galectin Therapeutics stock for Q4 2016, down 19% quarter-over-quarter.
  • 6 funds opened new Galectin Therapeutics positions in Q4 2016 and 8 closed out, a net change of -2 holders.
  • The largest Galectin Therapeutics buyer in Q4 2016 was D.A. Davidson & Co, an estimated $108K added.
  • The largest Galectin Therapeutics seller in Q4 2016 was Jacobs Levy Equity Management, an estimated $158K sold.

Based on aggregated 13F filings for Q4 2016.